World Heart Federation, Daiichi Sankyo and Lilly Partner to Improve Cardiovascular Health

ORLANDO, Florida - The World Heart Federation, Daiichi Sankyo Company, Limited (TSE: 4568)
and Eli Lilly and Company (NYSE: LLY) announced today that they have
partnered to improve cardiovascular health internationally. The organizations
made the announcement at the 58th Annual Scientific Session of the American
College of Cardiology in Orlando, Florida.

An estimated 17.5 million people died from cardiovascular disease in
2005, representing 30 percent of all global deaths, making it a significant
public health concern.(1)

Through this collaboration, Daiichi Sankyo and Lilly will reinforce the
World Heart Federation’s efforts addressing the challenges that result from a
cardiac event, such as a heart attack or stent placement. In particular, the
organizations will work together in emphasizing the importance of a heart
healthy lifestyle and adherence to medications for acute coronary syndrome
(ACS) patients.

“We find that people who have experienced a cardiac event often struggle
to cope with the physical and emotional impact,” said Pekka Puska, President
of the World Heart Federation. “This collaboration will support patients in
making the lifestyle changes that are critical during the recovery process
and beyond.”

Daiichi Sankyo and Lilly will support activities stemming from the World
Heart Federation’s 2009 World Heart Day, scheduled to take place on Sunday,
September 27 with a focus on workplace wellness.

About ACS

Acute coronary syndrome (ACS) is an umbrella term that includes unstable
angina (chest pain) and myocardial infarction (heart attack). ACS is
ultimately the result of coronary heart disease, which is the most severe
among cardiovascular diseases.

About the World Heart Federation

The World Heart Federation is a nongovernmental organization based in
Geneva Switzerland dedicated to the prevention and control of heart disease
and stroke, with a focus on low- and middle-income countries. It is comprised
of 195 member societies of cardiology and heart foundations from over 100
countries covering the regions of Asia-Pacific, Europe, East Mediterranean,
the Americas and Africa. For further information visit:
www.world-heart-federation.org.

About Daiichi Sankyo

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in
2005 through the merger of two leading Japanese pharmaceutical companies.
This integration created a more robust organization that allows for
continuous development of novel drugs that enrich the quality of life for
patients around the world. Areas of primary focus for Daiichi Sankyo’s
research and development are thrombotic disorders, malignant neoplasm,
diabetes mellitus, and autoimmune disorders. Equally important to the company
are hypertension, hyperlipidemia or atherosclerosis and bacterial infections.
For more information, visit www.daiichisankyo.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers — through medicines and
information — for some of the world’s most urgent medical needs.

(1) World Health Organization. Cardiovascular diseases. Fact Sheet No.
317. February 2007.

(Logo: www.newscom.com/cgi-bin/prnh/20090331/CL90914LOGO )

(Logo: www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )

Source: Eli Lilly and Company

Charanjit K. Jagait, World Heart Federation, +41-22-807-03-34 (office); Carole Copeland, Eli Lilly and Company, +1-317-277-3661 (office), +1-317-610-6196 (cell); Kimberly Wix, Daiichi Sankyo, +1-973-695-8338 (office), +1-908-656-5447 (cell) / Logo: https://www.newscom.com/cgi-bin/prnh/20090331/CL90914LOGO ; Logo: https://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO